Development and validation of a novel LC-MS/MS method for simultaneous quantitative determination of tyrosine kinase inhibitors in human plasma

Cancer Statistics, 2021

Rebecca L. Siegel, Kimberly D. Miller, Hannah E. Fuchs et al. · CA A Cancer Journal for Clinicians · 2021 · 17.1K citations · Full text

Epidemiology Of Cancer, Population Health Sciences, Cancer Registration +20

Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions

Solange Peters, Stefan Zimmermann, Alex A. Adjei · Cancer Treatment Reviews · 2014 · 152 citations

Oncology, Medicine, Drug–drug Interactions +7

Evaluation of the Practice of Antifungal Prophylaxis Use in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results From the SEIFEM 2010-B Registry

Livio Pagano, Morena Caira, Anna Candoni et al. · Clinical Infectious Diseases · 2012 · 83 citations · Full text

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib

Karthick Vishwanathan, Paul A. Dickinson, Karen So et al. · British Journal of Clinical Pharmacology · 2018 · 73 citations · Full text

Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor

Angela James, Catherine C. Smith, Mark R. Litzow et al. · Clinical Pharmacokinetics · 2020 · 67 citations · Full text